35.08MMarket Cap-0.81P/E (TTM)
1.130High1.100Low32.59KVolume1.120Open1.120Pre Close36.49KTurnover0.11%Turnover RatioLossP/E (Static)31.20MShares10.24052wk High0.92P/B34.90MFloat Cap1.02952wk Low--Dividend TTM31.04MShs Float450.000Historical High--Div YieldTTM2.68%Amplitude1.029Historical Low1.119Avg Price1Lot Size
Actinium Stock Forum
Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients
PR Newswire
5 mins ago
HIGHLIGHTS
Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study.
Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC confirmed...
Businesswire· 13 mins ago
NorthStar to support the development of YAP Therapeutics' innovative radiolabeled productsThis collaboration merges the expertise and resources from both companies, including NorthStar's state-of-the-art facilitiesThe agreement guarantees that YAP Therapeutics will receive clinical trial-read...
PR Newswire· 10 mins ago
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particleemittingradioisotope, actinium-225, for potential cancer treatm...
Actinium Announces Publication Of Phase 3 SIERRA Results Of Iomab-B - Quick Facts
Good lesson on the higher risks of biologics though. BLA (biologics license application) a relatively new classification (maybe 5 or so years?) meant to divert biologics from the NDA process that small molecule drugs go through.
In practical terms,...
Actinium Pharmaceuticals Inc - Iomab-B Well Tolerated in Older Relapsed/Refractory Aml Patients
September 05, 2024 08:00 AM Eastern Daylight Time!!! From this morning! BUT THIS ONE BELOW JUST WAS RELEASED VIA SEEKING ALPHA! NOT SURE IF THEY ARE MISPRINT OF DRUG? OR ANOTHER APPROVAL?
Perspective gets FDA fast track status for radiopharmaceutical VMT101
No comment yet